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Abstract
Hepatorenal syndrome (HRS) is one of themany potential causes of acute kidney injury (AKI) in patients with decompensated liver
disease. HRS is associated with poor prognosis and represents the end-stage of a sequence of reductions in renal perfusion induced
by progressively severe hepatic injury. The pathophysiology of HRS is complex with multiple mechanisms interacting simulta-
neously, although HRS is primarily characterised by renal vasoconstriction. A recently revised diagnostic criteria and
management algorithm for AKI has been developed for patients with cirrhosis, allowing physicians to commence treatment
promptly. Vasopressor therapy and other general management, such as antibiotic prophylaxis, need to be initiated whilst patients
are assessed for eligibility for transplantation. Liver transplantation remains the treatment of choice for HRS but is limited by
organ shortage. Other management options, such as transjugular intrahepatic portosystemic shunt, renal replacement therapy
and molecular absorbent recirculating system, may provide short-term beneﬁt for patients not responding to medical therapy
whilst awaiting transplantation. Clinicians need to be aware of the pathophysiology andmanagement principles of HRS to provide
quality care for patients with multi-organ failure.
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Introduction
Renal failure is common amongst patients with decompen-
sated cirrhosis and is associated with a poor prognosis, with
life expectancy ranging from weeks to months. Hepatorenal
syndrome (HRS) is a functional form of acute kidney injury
(AKI) characterised by renal vasoconstriction. Studies attempt-
ing to develop renal biomarkers to differentiate aetiologies
of AKI have shown promise, but such endeavour remains
in its infancy. There are different approaches to the manage-
ment of HRS, although liver transplantation still shows the
highest survival rates amongst patients with both hepatic
and renal failure (1). This review article will provide an
update on the pathophysiology, diagnostic criteria and treat-
ment options, including prophylaxis, in patients with HRS.
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Epidemiology
The incidence and the prevalence of HRS in patients with
advanced liver disease are approximately 7.6% and 13%,
respectively (2). HRS occurs predominantly in portal hyper-
tension associated with cirrhosis, but it has been described
in severe alcoholic hepatitis and fulminant hepatic failure
(3). HRS may occur either spontaneously or may be precipi-
tated by an acute insult, including spontaneous bacterial peri-
tonitis (SBP), non-steroidal anti-inﬂammatory drugs
(NSAIDs) or upper gastrointestinal bleeding.
Pathophysiology
There are a plethora of simultaneous mechanisms underlying
the pathophysiology of HRS, including arterial vasodilatory
effects, systemic inﬂammation, bacterial translocation and
hepatorenal reﬂex (4) (Figure 1). These mechanisms appear
to be mostly functional, as normalisation of kidney function
may be achieved either by pharmacotherapy or by liver
transplantation.
The arterial vasodilation theory
Arterial vasodilation appears to be the most plausible expla-
nation for circulatory dysfunction that occurs in patients with
cirrhosis and ascites (3). This involves two major mechanisms
as follows: ﬁrstly, systemic circulatory disturbances and,
secondly, activation of neurohumoral systems. Splanchnic
vasodilatation, resulting from portal hypertension secondary
to cirrhosis, leads to decreased systemic vascular resistance
and subsequent reduction in effective blood volume, which
is clinically mediated by an increased production of nitric
oxide (NO), carbon monoxide and/or endogenous cannabi-
noids (3). In the early stages, the effective arterial blood
volume and arterial pressure are maintained by increased
cardiac output resulting in a hyperdynamic circulation.
In later stages, the progressive splanchnic vasodilatation
results in a decrease in effective arterial blood volume that
can no longer be compensated by cardiac output. Moreover,
the subsequent decrease in cardiac output may be due to
cirrhotic cardiomyopathy, thereby contributing to further
arterial underﬁlling and worsening of renal function (4).
In order to maintain arterial pressure, systemic vasocon-
strictor systems, such as the renin-angiotensin-aldosterone
system (RAAS), the sympathetic nervous system (SNS) and
the non-osmotic hypersecretion of arginine vasopressin
(AVP), are activated leading to increased plasma renin activ-
ity and increased plasma norepinephrine levels. However, the
activation of neurohumoral systems has harmful impacts on
kidneys. Development of renal sodium and solute-free
water retention leads to ascites and oedema, and hypervole-
mic hyponatremia, respectively. This results in signiﬁcant
renal vasoconstriction, which leads to a decrease in
glomerular ﬁltration rate and subsequently HRS (5).
Renal factors
Prostaglandins (PGs), speciﬁcally PGI2 and PGE2, induce
renal vasodilation, thereby providing renal protective effects
by compensating for the vasoconstrictor systems of RAAS,
Activation of neurohumoral
system (RAAS, SNS, AVP)
Renal vasoconstriction
HRS-AKI
Hyponatremia and ascites
Sodium and water
retention
Neurally mediated
reflex
Activation of
chemoreceptors,
baroreceptors and
osmoreceptors in the liver
↓ Renal blood flow
↓ Effective arterial blood
volume
Splanchnic/systemic
arterial dilatation
Portal hypertension
Cirrhosis
Bacterial translocation
Inflammatory cytokines
(TNF, endotoxins)
Compensatory ↑ cardiac
output
Figure 1. Proposed mechanisms for pathophysiology of hepatorenal syndrome.
AVP, arginine vasopressin; RAAS, renin-angiotensin-aldosterone system; SNS, sympathetic nervous system; TNF, tumour
necrosis factor.
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SNS and AVP. The levels of renal PGs are increased in
patients with cirrhosis and ascites (6). NSAIDs are a common
cause of kidney failure in patients with cirrhosis (6), illustrat-
ing the probable important role of PG production for main-
taining renal function in patients with cirrhosis.
Cytokines and vasoactive mediators
Systemic inﬂammation plays a role in the pathophysiology of
HRS. Bacterial translocation has been implicated in the
haemodynamic derangement of cirrhotic patients, thereby
leading to HRS (4). In the clinical setting, increased levels of
pro-inﬂammatory cytokines, such as tumour necrosis factor
α (TNFα), interleukin-6 (IL-6) and NO, in the splanchnic
area lead to reduced systemic vascular resistance and
increased cardiac output (7).
Hepatorenal reflex
The existence of sensor(s) in the hepatic circulation, which play a
role in regulating extracellular ﬂuid volume, is pathologically sti-
mulated by hepatic haemodynamic irregularities. This may con-
tribute to volume overload and ascites by activating renal
sympathetic nerves to promote salt and water retention (8).
Diagnostic criteria
AKI is a frequent complication in patients with advanced
liver disease, with several potential causes. Recent consensus
guidelines have been published by the International Club of
Ascites (ICA) updating the recommended threshold for diag-
nosing AKI in patients with cirrhosis (Table 1), which now
align with the Kidney Disease Improving Global Outcomes
(KDIGO) AKI classiﬁcation (2). HRS is a diagnosis of exclu-
sion and should be suspected in patients presenting with
new renal impairment in the setting of cirrhosis with ascites.
Criteria for the diagnosis of HRS were ﬁrst published by
the ICA in 1996 with subsequent revisions (2, 9), and the cur-
rent recommended criteria are listed in Table 2. A vital step in
evaluating patients with potential HRS is to exclude other
possible causes of AKI.
HRS has traditionally been subdivided into Type 1 or Type
2 disease based on the rate of onset of AKI and prognosis.
Type 1 HRS is characterised by a rapid (less than 2 weeks)
onset of AKI, often precipitated by other events, in particular
SBP. Type 1 HRS is usually associated with a poor prognosis.
Type 2 HRS typically presents with a more insidious onset of
renal impairment over several weeks in patients with cirrhosis
and refractory ascites.
Currently, there are no clinical criteria to reliably distinguish
between HRS and other causes of AKI. This has prompted
researchers to search for biomarkers, such as urinary neutrophil
gelatinase-associated lipocalin (NGAL), with the potential to
aid the differential diagnosis and management of AKI occur-
ring in cirrhotic patients (4). However, these biomarkers are
yet to be validated in large randomised control trials and there-
fore cannot be routinely recommended in clinical practice yet.
Table 1. ICA-AKI new deﬁnitions for the diagnosis of AKI in patients with cirrhosis
Subject Deﬁnition
Baseline sCr
A value of sCr obtained in the previous 3 months, when
available, can be used as baseline sCr. In patients with more
than one value within the previous 3 months, the value closest
to the admission time to the hospital should be used.
In patients without a previous sCr value, the sCr on admission
should be used as baseline.
Deﬁnition of AKI
• Increase in sCr ≥0.3 mg/dl (≥26.5 μmol/L) within 48 h; or
• A percentage increase in sCr ≥50% from baseline that is
known, or presumed, to have occurred within the previous
7 days.
Staging of AKI
• Stage 1: increase in sCr ≥0.3 mg/dl (26.5 μmol/L) or an
increase in sCr ≥1.5-fold to 2-fold from baseline.
• Stage 2: increase in sCr >2-fold to 3-fold from baseline.
• Stage 3: increase of sCr >3-fold from baseline or sCr ≥4.0
mg/dl (353.6 μmol/L) with an acute increase ≥0.3 mg/dl
(26.5 μmol/L) or initiation of renal replacement therapy.
Reproduced with permission from Angeli et al. (2).
AKI, acute kidney injury; ICA, International Club of Ascites; sCr, serum creatinine.
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Prognosis
Prognosis is poor when patients with cirrhosis develop renal
impairment, and HRS is associated with the worst mortality
rate amongst the different causes of AKI in the setting of
cirrhosis (10). A study in 2005 showed the median survival
times for Type 1 HRS and Type 2 HRS to be 1 month and
6 months, respectively (11). Further prognostic studies with
the newly revised HRS diagnostic criteria will be required.
Management
The ICA has proposed a new algorithm for managing AKI
based on the ICA-AKI criteria, which potentially allows
patients to receive earlier treatment for AKI-HRS (Figure 2)
(2). Due to scarce supply of organs for transplantation,
medical treatments are often initiated ﬁrst.
Prevention of HRS
In patients with SBP, a meta-analysis of four randomised
trials demonstrated that treatment with antibiotics and albu-
min was associated with a signiﬁcant reduction in renal
impairment (8% vs. 31%) and mortality (16% vs. 35%) com-
pared with controls (12). Furthermore, another randomised
controlled trial reported that primary prophylaxis with nor-
ﬂoxacin reduced the incidence of SBP, delayed the develop-
ment of HRS and improved survival in patients with
cirrhosis, ascites and either advanced liver failure or
impaired renal function (13). The phosphodiesterase inhibi-
tor, pentoxifylline, which has anti-inﬂammatory properties
through inhibition of leukotriene and TNFα synthesis, was
included in management for prevention of HRS. However,
a recent randomised study demonstrated that pentoxifylline
is not statistically equivalent to the efﬁcacy of prednisolone
in patients with severe alcoholic hepatitis (14).
Vasoconstrictor therapy
Medical treatment for patients with suspected HRS usually
consists of vasopressor and albumin infusion, with the aims
of improving splanchnic arterial circulation and plasma
volume expansion, respectively. Several vasopressor thera-
pies have been trialled in HRS, including terlipressin, norepi-
nephrine and midodrine plus octreotide. Terlipressin is not
licensed for use in the United States nor is it on the Pharma-
ceutical Beneﬁcial Scheme (PBS) in Australia, whilst mido-
drine is only available through Special Assess Scheme
(SAS). A pooled analysis of 501 patients in 21 studies showed
that an increase in mean arterial pressure of at least 5 mmHg
correlated with improvement in renal function regardless of
which vasopressor was used (15).
A systematic review and meta-analysis of randomised
controlled trials of norepinephrine versus terlipressin in
patients with Type 1 HRS found no signiﬁcant difference in
reversal of HRS, mortality at 30 days or recurrence of HRS
(16). Furthermore, a recent study indicated that the efﬁcacy
of a midodrine plus octreotide regimen might not be as
signiﬁcant as previous studies suggested (17). In 2015, a
randomised controlled trial of 49 patients comparing terli-
pressin with octreotide/midodrine illustrated a signiﬁcantly
higher rate of improvement in renal function with terlipressin
(≥50% serum creatinine decrease, 70.4% vs. 28.6%, P = 0.01),
although there was no signiﬁcant difference in survival
between the two groups (18). Terlipressin is a bridging
option, despite its high cost, to liver transplantation in
patients who are transplant candidates as it may improve
both renal function and short-term survival for patients
awaiting a liver transplant. Further clinical trials will be
required to assess the indication, efﬁcacy and duration of dif-
ferent vasopressors under the new ICA-AKI criteria and
management algorithm.
Table 2. Diagnostic criteria of HRS type of AKI in patients with cirrhosis
HRS – AKI
• Diagnosis of cirrhosis and ascites
• Diagnosis of AKI according to ICA-AKI criteria
• No response after two consecutive days of diuretic withdrawal and plasma volume expansion with albumin 1 g per kg of
body weight
• Absence of shock
• No current or recent use of nephrotoxic drugs (NSAIDs, aminoglycosides, iodinated contrast media, etc.)
• No macroscopic signs of structural kidney injury*, deﬁned as:
○ Absence of proteinuria (>500 mg/day)
○ Absence of microhaematuria (>50 RBCs per high power ﬁeld)
○ Normal ﬁndings on renal ultrasonography
Reproduced with permission from Angeli et al. (2).
AKI, acute kidney injury; HRS, hepatorenal syndrome; ICA, International Club of Ascites; NSAIDs, non-steroidal anti-inﬂammatory drugs;
RBCs, red blood cells.
*Patients who fulﬁl these criteria may still have structural damage such as tubular damage.
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Transjugular intrahepatic portosystemic shunt
Although limited studies have suggested that transjugular
intrahepatic portosystemic shunt (TIPS) may lead to impro-
vement of renal function in a well-selected group of patients
(19), poor prognosis has been associated with patients with
advanced liver disease undergoing TIPS procedure (20). TIPS
aims to reduce portal pressure by inserting an intrahepatic
stent, which shunts portal blood into the systemic circulation,
and in theory may beneﬁt some patients with HRS. However,
many patients with HRS are ineligible for TIPS due to con-
traindications including severe hyperbilirubinaemia or Child-
Pugh class C (e.g., Bilirubin >5 mg/dL, Child-Pugh score >11).
Moreover, the risks associated with TIPS, namely hepatic ence-
phalopathy, liver failure, cardiac failure and renal injury due
to contrast, also need to considered (21).
Extracorporeal support systems
Renal replacement therapy (RRT) has been shown to
improve short-term survival in patients with AKI and may
provide a bridge to liver transplantation for patients with
HRS who are unresponsive to vasopressors and ineligible
for TIPS (22). However, in the absence of an acute reversible
component to the AKI or a plan for liver transplantation,
initiation and/or continuation of RRT should be evaluated
carefully, as these patients have a poor prognosis and are
unlikely to recover with RRT alone (22).
Molecular absorbent recirculating system (MARS)
removes albumin-bound and water-soluble substances,
including NO and TNF, which are involved in pathogenesis
of HRS. MARS has been shown to improve neurological
function and coagulation parameters although a randomised
trial of 189 patients reported no beneﬁcial effect on survival
of MARS therapy in patients with acute or chronic liver
failure (23).
Liver transplantation
The deﬁnitive treatment for Type 1 HRS is liver transplan-
tation, as this will reverse both portal hypertension and liver
failure, the two main factors leading to systemic circulatory
disturbances in HRS. A case-control study suggested that
patients with HRS treated with vasopressin before trans-
plantation had similar outcomes compared with patients
transplanted with normal renal function (24). However,
other studies have demonstrated that vasopressors, regard-
less of the agent used, had no signiﬁcant impact on survival
(1, 25). Simultaneous liver–kidney transplantation is not
necessary for patients with isolated HRS and should only
be considered in selected patients at high risk for non-recov-
ery of renal function, such as patients with heavy proteinuria
and other evidence of advanced primary renal disease.
Conclusion
HRS remains an important and life-threatening complica-
tion for patients with advanced liver disease. Recent
advances in the understanding of the pathophysiology of
HRS have identiﬁed potential targets for novel diagnostic
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Figure 2. Proposed algorithm for the management of acute kidney injury in patients with cirrhosis and ascites.
*Treatment of spontaneous bacterial peritonitis should include albumin infusion according to current guidelines.
#Initial AKI stage is deﬁned as AKI stage at the time of ﬁrst fulﬁlment of the AKI criteria.
AKI, acute kidney injury; HRS, hepatorenal syndrome; NSAIDs, non-steroidal anti-inﬂammatory drugs.
Reproduced with permission from Angeli et al. (2).
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and therapeutic approaches. HRS is now recognised as
HRS–AKI and the diagnostic criteria have recently been
revised. Whilst liver transplantation in appropriate patients
is the only deﬁnitive treatment for HRS, vasopressors and
albumin remain the key supportive medical therapy for
HRS-AKI. Novel biomarkers may play a future signiﬁcant
role in helping clinicians to identify the aetiology of AKI
in patients with cirrhosis.
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